Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Dupixent® (dupilumab) – Expanded indication
January 25, 2024 - Regeneron and Sanofi announced the FDA approval of Dupixent (dupilumab), for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
